Shots:
Several undulating factors coalesce to inadvertently shape the biopharma industry
Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.
Jesse Mendelsohn, SVP at Model N, emphasizes the…
Shots:
Kyle Forcier, Sr. Director of Life Science Product Marketing at Model N, addresses the challenges of the 340B program and ways manufacturers can mitigate them and emerge stronger
340B, a US federal government plan, enables eligible healthcare organizations and covered entities to receive outpatient drugs from drug manufacturers at significantly low prices
Kyle recalls…

